B cell-targeted therapy in autoimmune disease: Rationale, mechanisms, and clinical application

Journal of Rheumatology

Volumn 35, Issue 7, 2008, Pages 1245-1255

  Mease, Philip J ^a  

^a Seattle Rhumatology Associates   (United States)

Author keywords

Biologic therapy; CD20; Rheumatoid arthritis; Rituximab

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ATACICEPT; BELIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; EPRATUZUMAB; ETANERCEPT; FOLIC ACID; HYBRID PROTEIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OCRELIZUMAB; OFATUMUMAB; PARACETAMOL; PLACEBO; PREDNISOLONE; RECOMBINANT FUSION PROTEIN BR3 FC; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; TRU 015;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL THERAPY; CELL LINEAGE; CHILL; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEADACHE; HEPATITIS C; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; MONOTHERAPY; NAUSEA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; SINGLE DRUG DOSE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROAT DISEASE; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47349114745     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Lawrence RC, Heimick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
3. Smith JB, Haynes MK. Rheumatoid arthritis -a molecular understanding. Ann Intern Med 2002;136:908-22.
4. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97:188-96.
5. Panayi GS. The immunopathogenesis of rheumatoid arthritis. Br J Rheumatol 1993;32 Suppl:4-14.
6. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996;93:221-5.
7. Scrivo R, Di Franco M, Spadaro A, Valesini G. The immunology of rheumatoid arthritis. Ann NY Acad Sci 2007;1108:312-22.
8. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
9. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
10. Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007;56:1446-53.
11. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. N Engl J Med 2007;357:1199-209.
12. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
13. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
14. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
15. Raptopoulou A, Sidiropoulos P, Katsouraki M, Boumpas DT. Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts. Crit Rev Clin Lab Sci 2007;44:339-63.
16. Silverman GJ, Carson DA. Review: roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003;5 Suppl 4:S1-S6.
17. O'Neill SK, Shlomchik MJ, Giant TT, Cao Y, Doodes PD, Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 2005;174:3781-8.
18. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.
19. Lund FE, Garvy BA, Randall TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005;8:25-54.
20. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000;12:471-81.
21. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-50.
22. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82.
23. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489-501.
24. Edwards IC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006;20:915-28.
25. Mannik M, Nardella FA. IgG rheumatoid factors and self-association of these antibodies. Clin Rheum Dis 1985;11:551-72.
26. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85.
27. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-7.
28. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998;48:125-32.
29. Cragg MS, Walshe CA, Ivanov AO. Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74.
30. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005;4:526-31.
31. Janas E, Priest R, Malhotra R. Functional role of lipid rafts in CD20 activity? Biochem Soc Symp 2005;72:165-75.
32. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92.
33. Kehrl JH, Riva A, Wilson GL, Thevenin C. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 1994;15:432-6.
34. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584-91.
35. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8.
36. Protheroe A, Edwards JC, Simmons A, Maclennan K, Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology Oxford 1999;38:1150-2.
37. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology Oxford 2001;40:205-11.
38. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
39. de Vita S, Zaja F, Sacco S, de Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-33.
40. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
41. Strand V, Balbir-Gurman A, Pavelka K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology Oxford 2006;45:1505-13.
42. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
43. Emery P, Fleischmann R, Pevelka K, et al. Safety and tolerability of rituximab retreatment in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 2005;52 Suppl:S341.
44. Fleischmann RM, Pavelka K, Baldassare AR, et al. Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 2005;52 Suppl:S131.
45. Mease PJ, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in the DANCER trial [abstract]. Ann Rheum Dis 2006;65 Suppl:332.
46. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
47. Keystone E, Furie R, Burmester GR, et al. Rituximab plus methotrexate improves quality of life in patients with active rheumatoid arthritis despite previous treatment with one or more TNF inhibitors [abstract]. Ann Rheum Dis 2006;65 Suppl:631.
48. Kielhorn A, Bombardieri S, Aultman R, Jost F, Magrini F. Rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study [abstract]. Ann Rheum Dis 2006;65 Suppl:324.
49. Emery P, Furst DE, Ferraccioli G, et al. Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs [abstract]. Ann Rheum Dis 2007;66 Suppl:430.
50. Keystone E, Fleischmann RM, Emery P, et al. Repeated treatment courses of rituximab in rheumatoid arthritis: sustained efficacy in patients with an inadequate response to one or more TNF inhibitors [abstract]. Ann Rheum Dis 2007;66 Suppl:432.
51. van Vollenhoven R, Emery P, Bingham C, et al. Long-term safety data from extended follow-up and repeat use of rituximab in rheumatoid arthritis [abstract]. Ann Rheum Dis 2007;66 Suppl:88.
52. Tak PP, Mease P, Bombardieri S, et al. Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors [abstract]. Ann Rheum Dis 2006;65 Suppl:503.
53. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999;26 Suppl:79-87.
54. Emery P, Sheeran T, Lehane PB, Saiedabadi N, Shaw TM. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 2004;50 Suppl:S659.
55. Keystone E, Fleischmann R, Emery P, et al. Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors [abstract]. Ann Rheum Dis 2006;65 Suppl:323.
56. Fleischmann R, van Vollenhoven R, Udell J, et al. Infusion-associated events decrease with repeat courses of rituximab in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 2006;54 Suppl:S238.
57. Moreland LW, van Vollenhoven RF, Emery P, et al. Safety of rituximab in rheumatoid arthritis: results of a pooled analysis [abstract]. Ann Rheum Dis 2006;65 Suppl:332.
58. Genovese M, Emery P, Ruderman E, et al. Immunoglobulin levels and infection rates in patients with rheumatoid arthritis treated with repeated courses of rituximab [abstract]. Arthritis Rheum 2007;56 Suppl:S149.
59. Rituxan® [rituximab] prescribing information. [Internet. Updated 2007 Feb; cited February 19, 2008.] Available from: http://www.gene.com/gene/ products/information/pdf/rituxan-prescribing.pdf.
60. van Vollenhoven RF, Cohen S, Pavelka K, et al. Response to rituximab in patients with rheumatoid arthritis is maintained by repeat therapy: results of an open-label trial [abstract]. Ann Rheum Dis 2006;65 Suppl:510.
61. Mease P, Keystone E, Kaell A, et al. Recent disease activity affects outcome of second course of rituximab for RA [abstract]. Arthritis Rheum 2006;54 Suppl:S236.
62. Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2007;58:5-14.
63. Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab (HuMax-CD20), a fully human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis. Early results from an ongoing, double-blind, randomized, placebo controlled clinical trial [abstract]. Ann Rheum Dis 2007;66:124.
64. Genovese M, Kaine J, Lowenstein M, et al. Ocrelizumab, a novel humanized anti-CD20 antibody: week 72 results from a Phase I/II clinical trial in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2007;56 Suppl:695.
65. Burge D, Chopiak V, Dvoretskiy L, et al. TRU-015 improves rheumatoid arthritis disease activity in a randomized, double-blind, placebo-controlled, multi-center Phase 2 dose ranging trial [abstract]. Arthritis Rheum 2007;56 Suppl:L7.
66. McKay J, Chwalinska-Sadowska H, Boling E, et al. Belimumab (BmAb), a fully human monoclonal antibody to B-Lymphocyte Stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogenous subject population [abstract]. Arthritis Rheum 2005;52 Suppl:S710.
67. Peano S, Ponce R, Bertolino M, Vigna E, Yu P, Visich J. Nonclinical safety, pharmacokinetics, and pharmacodynamics of TACI-Ig, a soluble receptor fusion protein antagonist of BLyS (B Lymphocyte Stimulator) and APRIL (a proliferation-inducing ligand) [abstract]. Arthritis Rheum 2005;52 Suppl:S285.
68. Tak PP, Thurlings RM, Dimic A, et al. A Phase Ib study to investigate atacicept (TACI-Ig) In patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2006;54 Suppl:L36.
69. Shaw M, Del Giudice J, Trapp R, et al. The safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects of repeated doses of BR3-Fc in patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2007;56 Suppl: 1432.
70. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
71. Albert AD, Khan RS, Stanbury J, Tsai D, Eisenberg AR. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus [abstract]. Arthritis Rheum 2003;48 Suppl:LB9.
72. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
73. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multi-center phase WI trial of rituximab for treatment of refractory systemic lupus erythematosus [abstract]. Arthritis Rheum 2006;54 Suppl:S258.
74. Ng KP, Leandro MJ, Edwards JC, Cambridge G, Isenberg DA. Long term follow up of patients with systemic lupus erythematosus (SLE) after B cell depletion [abstract]. Arthritis Rheum 2006;54 Suppl:S258.
75. Jonsdottir T, Gunnarsson I, Risselada AP, Klareskog L, van Vollenhoven RF. Rituximab plus cyclophosphamide in severe SLE. Ann Rheum Dis 2006;65 Suppl:200.
76. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90.
77. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13.
78. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobsson SH, Welin-Henriksson E, van Vollenhoven RF. Histopathological and clinical changes in 7 patients with severe proliferative lupus nephritis treated with rituximab plus cyclophosphamide: a rebiopsy study [abstract]. Arthritis Rheum 2006;54 Suppl:S823.
79. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56.
80. Food and Drug Administration. Rituximab. Information for healthcare professionals. [Internet. Updated 2006 Dec 18; cited 2007 Dec 14. Available from: http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf. February 19, 2008.]
81. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56:2116-28.
82. Wallace DJ, Lisse J, Stohl W, et al. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), shows bioactivity and reduces systemic lupus erythematosus disease activity [abstract]. Ann Rheum Dis 2006;65 Suppl:62.
83. Merrill JT, Wallace DJ, Stohl W, et al. Safety profile of belimumab (fully human monoclonal antibody to BLyS) in patients with systemic lupus erythematosus (SLE) treated during a placebo-controlled trial and in a long-term continuation study [abstract]. Arthritis Rheum 2007;56 Suppl:427.
84. Dall'Era M, Chakravarty E, Genovese M, et al. Trial of atacicept in patients with systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheum 2006;54 Suppl:L19.
85. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.
86. Pijpe J, Bootsma H, Spijkervet FKL, Vissink A, Kallenberg CGM, Ihrler S. Rituximab treatment in Sjogren's syndrome: clinical-histological evidence of the efficacy of B-cell depletion. Ann Rheum Dis 2006;65 Suppl:106.
87. Meijer JM, Pijpe J, van Imhoff GW, et al. (Re)treatment with rituximab in patients with active primary Sjogren's syndrome. Ann Rheum Dis 2006;65 Suppl:476.
88. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007;66:351-7.
89. Steinfeld SD, Pradier O, Song I, et al. Epratuzumab (anti-CD22) for the treatment of primary Sjogren's syndrome [abstract]. Arthritis Rheum 2005;52 Suppl:S277.
90. Zaja F, de Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
91. Sansonno D, de Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26.
92. Ghijsels E, Lernt E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004;43:e34-e38.
93. Gallien S, Le Guera V, Cohen P, Marien M, Mouthon L, Guillevin L. Tolerance and efficacy of rituximab for type II mixed cryoglobulinemia (MC) [abstract]. Ann Rheum Dis 2006;65 Suppl:373.
94. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8.
95. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
96. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.